6L7A Stock Overview
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bellerophon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$11.15 |
| 52 Week Low | US$0.32 |
| Beta | 0.55 |
| 1 Month Change | -3.58% |
| 3 Month Change | -8.38% |
| 1 Year Change | -69.22% |
| 3 Year Change | -94.93% |
| 5 Year Change | -96.52% |
| Change since IPO | -97.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6L7A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.5% |
| 1Y | -69.2% | -22.8% | 1.3% |
Return vs Industry: 6L7A underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 6L7A underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 6L7A volatility | |
|---|---|
| 6L7A Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6L7A's share price has been volatile over the past 3 months.
Volatility Over Time: 6L7A's weekly volatility has decreased from 38% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | n/a | bellerophon.com |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
Bellerophon Therapeutics, Inc. Fundamentals Summary
| 6L7A fundamental statistics | |
|---|---|
| Market cap | €635.45k |
| Earnings (TTM) | -€11.71m |
| Revenue (TTM) | €5.33m |
0.1x
P/S Ratio-0.1x
P/E RatioIs 6L7A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6L7A income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.64m |
| Other Expenses | US$18.04m |
| Earnings | -US$12.40m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 100.00% |
| Net Profit Margin | -219.88% |
| Debt/Equity Ratio | 0% |
How did 6L7A perform over the long term?
See historical performance and comparison